

GLAXOSMITHKLINE PLC
Form 6-K
February 24, 2009

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending February 2009

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of Dr M M Slaoui, a Person Discharging Managerial Responsibility, in the Ordinary shares of GlaxoSmithKline plc following the sale of Ordinary shares at a price of £11.33 per Ordinary share on 23 February 2009 by his connected person, who is also employed by the Company, to meet her tax liabilities following the vesting of a Share Value Plan award:

| | No. of Shares Awarded | No. of Shares Sold | No. of Shares Retained |
|------------------------------|----------------------------------|---------------------------|-------------------------------|
| Mrs Claudine Bruck Slaoui | 1,200 | 355 | 845 |

The Company and Dr Slaoui's connected person were advised of these transactions on 24 February 2009.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Deputy Company Secretary

24 February 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 24 2009

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc